Diabetic Kidney Disease (DKD) is the most frequent cause for end stage renal disease (ESRD). The UCLA Diabetic Kidney Disease (DKD) Program strives to accomplish by providing comprehensive patient care, education and performing the research with new medications and advances. There is an increasing need for new therapeutic agents that effectively target underlying disease mechanisms and slow the progression of kidney disease, as the type 2 diabetes mellitus population rapidly grows throughout the world within the next years and with it the DKD population.
Interventions to improve outcomes related to DKD focus on reducing risk, including counseling on lifestyle modifications (i.e. smoking cessation and dietary modifications to reduce proteinuria and aid in weight loss) and interventions aimed at glycemic control, dyslipidemia, and hypertension.
The UCLA diabetic kidney program is committed to ongoing research, including basic science, applied clinical science, outcomes, and evidence-based research, in the mission to develop new treatments and cures for Diabetic kidney disease.
Learn how you can support the DKD Program by visiting giving.ucla.edu/kidney.
